Dr. Rini Discusses the Findings of IMmotion151 in RCC

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma (RCC).

IMmotion151 is a phase III, randomized study of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with untreated PD-L1—positive metastatic RCC. Findings thus far have shown a reduction in the risk of progression or death by 26% compared with sunitinib (Sutent). Additionally, the median progression-free survival by investigator assessment for PD-L1 expressers on ≥1% of immune cells (n = 362) was 11.2 months (95% CI, 8.9-15.0) with atezolizumab and bevacizumab compared with 7.7 months (95% CI, 6.8-9.7) with sunitinib (HR, 0.74; 95% CI, 0.57-0.96; P = .0217).

At the 2018 ASCO Annual Meeting, Rini presented the patient-reported outcomes. Reports concluded that while on atezolizumab plus bevacizumab, patients maintained a good quality of life with minimum symptom interference versus sunitinib. Patients who received the combination had less symptom severity, and milder toxicities than those who received sunitinib.